Standard BioTools Inc. (LAB) Income Statement Analysis

See more : Integra Essentia Limited (ESSENTIA.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Standard BioTools Inc. (LAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Standard BioTools Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Grupo Minsa, S.A.B. de C.V. (MINSAB.MX) Income Statement Analysis – Financial Results
Amerigo Resources Ltd. (ARG.TO) Income Statement Analysis – Financial Results
New Plus Knitting Public Company Limited (NPK.BK) Income Statement Analysis – Financial Results
Sensortek Technology Corp. (6732.TWO) Income Statement Analysis – Financial Results
Viscogliosi Brothers Acquisition Corp. (VBOCW) Income Statement Analysis – Financial Results

Standard BioTools Inc. (LAB)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.fluidigm.com

About Standard BioTools Inc.

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2001
Revenue	106.34M	97.95M	130.58M	138.14M	117.24M	112.96M	101.94M	104.45M	114.71M	116.46M	71.18M	52.33M	42.87M	33.56M	25.41M	15.35M	7.28M	6.40M	130.58M
Cost of Revenue	55.89M	60.90M	61.21M	54.82M	52.96M	51.32M	49.96M	46.01M	46.63M	42.85M	20.08M	15.33M	13.19M	11.58M	11.49M	8.36M	3.51M	2.77M	53.32M
Gross Profit	50.45M	37.05M	69.37M	83.33M	64.28M	61.65M	51.98M	58.44M	68.08M	73.61M	51.10M	37.01M	29.67M	21.98M	13.93M	6.98M	3.76M	3.63M	77.27M
Gross Profit Ratio	47.44%	37.83%	53.13%	60.32%	54.83%	54.57%	50.99%	55.95%	59.35%	63.21%	71.79%	70.72%	69.23%	65.49%	54.80%	45.50%	51.70%	56.66%	59.17%
Research & Development	25.95M	38.50M	37.94M	36.46M	31.64M	30.03M	30.83M	38.42M	39.26M	43.42M	19.73M	16.60M	13.94M	13.01M	12.32M	14.02M	14.39M	15.59M	37.94M
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	87.54M	114.76M	98.89M	97.90M	84.48M	79.78M	79.52M	93.21M	82.96M	71.32M	48.06M	38.48M	31.30M	23.55M	19.65M	22.51M	12.90M	9.70M	98.89M
Other Expenses	0.00	-12.31M	7.63M	507.00K	1.43M	637.00K	385.00K	-1.17M	-1.16M	-857.00K	502.00K	-189.00K	0.00	0.00	0.00	0.00	0.00	0.00	7.89M
Operating Expenses	113.49M	153.26M	136.83M	134.36M	116.12M	109.81M	110.34M	131.63M	122.22M	114.75M	67.79M	55.08M	45.24M	36.55M	31.96M	36.53M	27.29M	25.29M	144.73M
Cost & Expenses	169.38M	214.15M	198.04M	189.18M	169.08M	161.13M	160.30M	177.64M	168.85M	157.60M	87.87M	70.41M	58.43M	48.13M	43.45M	44.89M	30.80M	28.06M	198.04M
Interest Income	0.00	4.33M	291.00K	307.00K	1.33M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.00K	37.00K	766.00K	1.14M	565.00K	0.00
Interest Expense	4.57M	4.33M	3.82M	3.57M	4.28M	13.89M	5.82M	5.82M	5.81M	5.34M	14.00K	628.00K	3.10M	2.16M	2.88M	2.03M	2.79M	2.26M	-3.82M
Depreciation & Amortization	15.18M	15.03M	16.07M	17.94M	15.81M	16.50M	18.30M	17.94M	16.12M	4.06M	2.55M	1.48M	1.06M	1.50M	1.94M	1.97M	2.14M	1.46M	0.00
EBITDA	-54.46M	-173.57M	-43.77M	-34.61M	-46.62M	-31.03M	-39.68M	-56.42M	-32.87M	-38.50M	-13.82M	-16.78M	-18.14M	-13.52M	-14.67M	-26.12M	-20.91M	-19.83M	-67.46M
EBITDA Ratio	-51.21%	-115.87%	-33.89%	-25.05%	-29.51%	-27.40%	-38.62%	-54.02%	-34.16%	-32.58%	-19.15%	-32.06%	-33.84%	-38.92%	-63.20%	-174.69%	-278.32%	-306.96%	-51.66%
Operating Income	-76.60M	-116.21M	-67.46M	-51.04M	-51.84M	-48.16M	-58.36M	-73.19M	-50.16M	-51.84M	-17.95M	-18.07M	-18.57M	-14.57M	-18.04M	-29.54M	-23.53M	-21.66M	-67.46M
Operating Income Ratio	-72.03%	-118.64%	-51.66%	-36.94%	-44.22%	-42.64%	-57.25%	-70.07%	-43.72%	-44.51%	-25.22%	-34.53%	-43.31%	-43.42%	-70.98%	-192.50%	-323.38%	-338.59%	-51.66%
Total Other Income/Expenses	2.40M	-76.72M	3.80M	-3.07M	-14.87M	-13.26M	-5.44M	-6.99M	-4.64M	-5.87M	2.26M	-817.00K	-3.74M	-2.25M	-1.14M	-103.00K	-1.82M	-1.89M	3.80M
Income Before Tax	-74.20M	-192.93M	-63.66M	-54.10M	-66.71M	-61.42M	-63.80M	-80.18M	-54.79M	-57.71M	-15.69M	-18.89M	-22.30M	-16.82M	-19.18M	-29.65M	-25.35M	-23.55M	-63.66M
Income Before Tax Ratio	-69.78%	-196.97%	-48.75%	-39.16%	-56.89%	-54.37%	-62.59%	-76.76%	-47.76%	-49.55%	-22.03%	-36.09%	-52.03%	-50.12%	-75.47%	-193.17%	-348.40%	-368.13%	-48.75%
Income Tax Expense	452.00K	-2.83M	-4.42M	-1.08M	-1.92M	-2.41M	-3.26M	-4.19M	-1.48M	-4.88M	137.00K	136.00K	166.00K	83.00K	-50.00K	-147.00K	105.00K	194.00K	-4.42M
Net Income	-74.66M	-190.10M	-59.24M	-53.02M	-64.79M	-59.01M	-60.54M	-75.99M	-53.32M	-52.83M	-15.82M	-19.02M	-22.47M	-16.90M	-19.13M	-29.50M	-25.45M	-23.55M	-59.24M
Net Income Ratio	-70.21%	-194.08%	-45.36%	-38.38%	-55.26%	-52.24%	-59.38%	-72.75%	-46.48%	-45.36%	-22.23%	-36.35%	-52.42%	-50.36%	-75.27%	-192.21%	-349.84%	-368.13%	-45.36%
EPS	-0.94	-2.43	-0.78	-0.74	-0.97	-1.49	-1.84	-2.62	-1.86	-1.90	-0.62	-0.86	-1.26	-0.89	-11.02	-17.85	-13.47	-12.46	0.00
EPS Diluted	-0.94	-2.43	-0.78	-0.74	-0.97	-1.49	-1.84	-2.62	-1.86	-1.90	-0.62	-0.86	-1.26	-0.89	-11.02	-17.85	-13.47	-12.46	0.00
Weighted Avg Shares Out	79.16M	78.31M	75.79M	72.04M	66.78M	39.65M	32.98M	29.01M	28.71M	27.77M	25.48M	22.14M	17.85M	18.98M	1.74M	1.65M	1.89M	1.89M	0.00
Weighted Avg Shares Out (Dil)	79.16M	78.31M	75.79M	72.04M	66.78M	39.65M	32.98M	29.01M	28.71M	27.77M	25.48M	22.14M	17.85M	18.98M	1.74M	1.65M	1.89M	1.89M	0.00

Penny Stocks To Buy Now? Insiders Threw Big Money At These 4 Stocks

May 3, 2022pennystocks.com

Penny stocks to buy according to these insiders. The post Penny Stocks To Buy Now?

Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results

April 22, 2022globenewswire.com

SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday,...